CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-09-04 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −119 | $19.71 | $2K | 92,083 |
| 2025-09-03 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −454 | $18.20 | $8K | 92,202 |
| 2025-08-27 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −470 | $17.31 | $8K | 92,656 |
| 2025-07-01 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −815 | $14.65 | $12K | 88,787 |
| 2025-05-15 | Williams Brinkley Ruth Director | Grant or award | +6,500 | 25,750 | ||
| 2025-05-15 | Williams Brinkley Ruth Director | Grant or award · Stock option (right to buy) | +19,500 | 19,500 | ||
| 2025-05-15 | Squarer Ron Director | Grant or award | +6,500 | 35,375 | ||
| 2025-05-15 | Squarer Ron Director | Grant or award · Stock option (right to buy) | +19,500 | 19,500 | ||
| 2025-05-15 | Poole Sandra Director | Grant or award | +6,500 | 30,000 | ||
| 2025-05-15 | Poole Sandra Director | Grant or award · Stock option (right to buy) | +19,500 | 19,500 | ||
| 2025-05-15 | Orwin John A Director | Grant or award | +6,500 | 35,375 | ||
| 2025-05-15 | Orwin John A Director | Grant or award · Stock option (right to buy) | +19,500 | 19,500 | ||
| 2025-05-15 | Meckler Jeffrey A Director | Grant or award | +6,500 | 87,500 | ||
| 2025-05-15 | Meckler Jeffrey A Director | Grant or award · Stock option (right to buy) | +19,500 | 19,500 | ||
| 2025-05-15 | LYONS GARY A Director | Grant or award | +6,500 | 57,500 | ||
| 2025-05-15 | LYONS GARY A Director | Grant or award · Stock option (right to buy) | +19,500 | 19,500 | ||
| 2025-05-15 | COUGHLIN TIMOTHY Director | Grant or award | +6,500 | 55,500 | ||
| 2025-05-15 | COUGHLIN TIMOTHY Director | Grant or award · Stock option (right to buy) | +19,500 | 19,500 | ||
| 2025-05-15 | Bruhn Suzanne Louise Director | Grant or award | +6,500 | 28,750 | ||
| 2025-05-15 | Bruhn Suzanne Louise Director | Grant or award · Stock option (right to buy) | +19,500 | 19,500 |
Page 17 of 51 · 1,020 trades